Allogene Therapeutics
A biotechnology company catalyzing cancer treatment through the development of CAR T therapy
214 employees · est. 2017 · South San Francisco, United...
Eiger BioPharmaceuticals
Developing innovative therapies to treat and cure rare metabolic diseases
25 employees · est. 2008
Eiger BioPharmaceuticals is the older company (2017 vs 2008); Allogene Therapeutics is the larger of the two.
Side-by-Side Comparison
| Metric | Allogene Therapeutics | Eiger BioPharmaceuticals |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2008 older |
| Headquarters | ||
| Headquarters | South San Francisco, United States | Not tracked yet |
| Employees | ||
| Employees | 214 larger | 25 |
| Industry | ||
| Industry | Biotechnology | Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | IPO | Post Ipo Debt |
| Total Funding | ||
| Total Funding | $1.05B | $156.26M |
| Funding Rounds | ||
| Funding Rounds | 4 | 10 |
| Services | ||
| Services | Development of CAR T cell products, Clinical trial management, Gene editing and engineering, Manufacturing of allogeneic therapies, Therapeutic innovation for cancer and autoimmune diseases | Not tracked yet |
| Target Customers | ||
| Target Customers | Patients with blood cancers, Patients with solid tumors, Patients with autoimmune diseases, Healthcare providers, Biopharmaceutical partners | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Clinical-stage, Cancer Treatment, Immunotherapy, CAR T Therapy, AlloCAR T Products, Allogeneic Therapies, Oncology, Autoimmune Disease, Cell Therapy, Therapy Development, Biopharmaceuticals, Medical Innovation, South San Francisco | Biopharmaceutical, Rare Metabolic Diseases, Innovative Therapies, Clinical Programs, GLP-1 Antagonist, Orphan Disease, Hepatitis Delta, Antiviral Therapy, Breakthrough Therapy Designation, Drug Development, Management Team, Commercialization, Patient Safety, Cost-Efficient, Therapeutics |
| Website | ||
| Website | allogene.com | eigerbio.com |
About Allogene Therapeutics
Allogene Therapeutics, based in South San Francisco, is a clinical-stage biotechnology company spearheading the evolution of cancer treatment with its innovative AlloCAR T products. Founded in 2017, the company is at the forefront of developing allogeneic chimeric antigen receptor T cell therapies,...
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a commercial-stage biopharmaceutical company founded in 2008 with a focus on developing innovative therapies for rare metabolic diseases. The company's slogan, "Developing innovative therapies to treat and cure rare metabolic diseases," reflects its primary objective. Eig...
We will tell you when either one moves
BounceWatch watches Allogene Therapeutics and Eiger BioPharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Allogene Therapeutics and Eiger BioPharmaceutica... — by email.
Frequently Asked Questions
Compare Allogene Therapeutics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Allogene Therapeutics on 9 Jun 2026, and Eiger BioPharmaceuticals on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
